Document:

Acknowledgement Agreement

 Exhibit 10.111 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 February 22, 2008 
 Steve Warren 
 Vice Provost for Research and Graduate Studies 

and President of the KU Center for Research, Inc. 

The University of Kansas 
 2385 Irving Hill Road

 Lawrence, Kansas 66045 
 Re:
Acknowledgement 
 Dear Steve: 
 In the course of reviewing our files, it has come to our attention that certain aspects of the agreements and assignments between CyDex Pharmaceuticals, Inc., formerly CyDex, Inc.
(“CyDex”) and CyDex L.C., and The University of Kansas (“KU”) (collectively, the “Agreements”) may be unclear or ambiguous. By signing below, each of KU and CyDex confirm the
following: 
 1. The Option Agreement between KU and Pfizer Inc. (“Pfizer”), effective December 3,
1993, was assigned under the Option Agreement Assignment, made November 5, 1993 and executed November 8, 1993 by KU, despite the incorrect reference to the date of the Option Agreement in the Option Agreement Assignment. 

2. The License Agreement between KU and CyDex L.C., effective September 3, 1993 (as amended in the Letter Amendment to License
Agreement, effective February 25, 1998, and the Second Amendment to License Agreement, effective August 4, 2004), granted to CyDex L.C. all of the rights necessary for CyDex L.C. to (i) enter into the Exclusive and ‘Nonexclusive
License Agreements with Pfizer, both effective June 4, 1996 (collectively the “Pfizer Licenses”) and (ii) assume all of the rights and obligations of KU under such Pfizer Licenses. 

3. The Agreements and all rights thereunder that may have been previously held by CyDex L.C. have been properly transferred and/or
assigned by CyDex L.C. to CyDex, Inc. 
 4. The [***] shares of Series A-1 Preferred Stock of CyDex (the
“Shares”) issued to the University of Kansas Center for Research, Inc. (the “Center for Research”) under that Stock Purchase Agreement dated as of August 4, 2004 and currently having a liquidation
preference of [***] per share under CyDex’s Amended and Restated Certificate of Incorporation, constitute all shares of Series A-1 Preferred Stock required to be issued by CyDex under Section 1 of that Second Amendment to License Agreement

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 CyDex Logo 

 
between CyDex and KU (the “Second Amendment”) and that the issuance of such Shares to the Center for Research fulfills in all respects CyDex’s obligation to issue
shares under the Second Amendment and that CyDex has fully paid for the rights granted to CyDex thereunder. 
 Please sign the
enclosed copy of this letter and return it to my attention by fax to (913) 685-8856, with the original to follow by mail at your earliest convenience. 
 We are grateful for your kind assistance and appreciate your prompt attention to this matter. If you have any questions, please do not hesitate to call me at (913) 402-3550. 

 

	
	Sincerely,
	
	/s/ John M. Siebert
	
	John M. Siebert, Chief Executive Officer
	CyDex Pharmaceuticals, Inc.

  

			
	Acknowledged and Agreed:
	
	The University of Kansas
		
	By:	 	 /s/ Steve Warren

			
		
	Name:	 	Steve Warren
	
	Title: Vice Provost for Research and Graduate Studies and President of the KU Center for Research,
Inc.

			
		
	Date:	 	 3-3-08License Agreement

 Exhibit 10.112 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 Execution Copy 
 LICENSE AGREEMENT 
  
 This LICENSE AGREEMENT (“Agreement”) is made and entered into as of January 4, 2006, (“Effective Date”) by and between CyDex, Inc. (“CyDex” or
“Licensor”), a corporation with its principal place of business located at 10513 W. 84th Terrace, Lenexa, Kansas 66214, and PRISM PHARMACEUTICALS, INC. (“Prism” or “Licensee”), a Delaware
corporation, with its principal place of business located at 1150 First Ave, Suite 1050, King of Prussia, Pennsylvania, 19406, each a “Party” and together the “Parties.” 

WHEREAS, CyDex is the owner of certain patents and rights relating to Captisol-enabled® Amiodarone and certain related compounds, as are further defined below, and; 

WHEREAS, Prism desires to obtain an exclusive worldwide license to develop, market, make, have made, use, distribute, offer for sale,
sell, import and export products by practicing said patents, and; 
 WHEREAS, Prism desires to develop said products, without
limitation, including but not limited to process development, non-clinical development, clinical development, and manufacture, and; 
 WHEREAS, CyDex is willing to grant to Prism said license under said patents, subject to the terms and limitations set forth herein; 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the
receipt and sufficiency of which each Party acknowledges, the Parties hereto agree as follows: 
  

	1.	DEFINITIONS. 

 1.1
“Approval” shall mean the first effective date on which sales of a new drug may begin, in accordance with a new drug approval received from FDA. 

1.2 “Captisol”® means the [***] -based solubility technology. 
 1.3 “Captisol”® Supply Agreement”
shall have the meaning set forth in Section 10.3. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 1.4 “CyDex” means CyDex, Inc. and any subsidiary or any other entity
in which CyDex, Inc., directly or indirectly, owns more than 50% of the voting securities, partnership, or other ownership interest. 
 1.5 “Confidential Information” shall mean any proprietary, confidential information (whether or not patentable or copyrightable), whether or not so marked, that is not generally
known to third parties and that has actual or potential economic value by reason of not being generally known. Confidential Information includes, without limitation, trade secrets, and nonpublic know-how, data, processes, formulas, methods,
technology, manufacturing techniques, cost and pricing information, sales and marketing information, and information of third parties held by a Party in confidence. Documents and things containing or embodying Confidential Information are
Confidential Information. Confidential Information does not include information that: 
  

	 	(a)	was known to the receiving party, as evidenced by the receiving party’s written records, before receipt from the disclosing party; 

 

	 	(b)	is disclosed to the receiving party by a third person who is under no obligation of confidentiality to the disclosing party hereunder with respect to such information
and who otherwise has a right to make such disclosure; 

  

	 	(c)	is or becomes generally known to the public through no fault of the receiving party; 

 

	 	(d)	is independently developed by the receiving party, as established by the receiving party’s contemporaneous written records, without access to or reliance on the
other Party’s Confidential Information; or 

  

	 	(e)	is required to be disclosed by law, rule or regulation of any court or regulatory authority of competent jurisdiction; provided, that a Party required to disclose the
other Party’s Confidential Information shall notify the other Party as soon as possible and, if requested by the other Party, use reasonable good faith efforts, at its own expense, to assist in seeking a protective order (or equivalent
protection) with respect to such disclosure or otherwise take reasonable steps to avoid making such disclosure. 

1.6 “Default” shall have the meaning set forth in Section 17.1.3(b). 

1.7 “Effective Date” means the date first set forth above. 

1.8 “Encumbrance” means any mortgage, charge, lien, security interest, easement, right of way, pledge or
encumbrance of any nature whatsoever. 
 1.9 “FDA” means the U.S. Food and Drug Administration.

 1.10 “FDA Communication” shall mean any communication or inquiry to or from the FDA related to the
Product Intellectual Property or Licensed Products, including but not limited to communications which are verbal, electronic, written, formal submissions, chronological files and any other record of any communication. 

1.11 “Fees” shall have the meaning set forth in Section 9.1. 

  
 -2-

 1.12 “Field of Use” or “Field” means all
uses in humans and animals. 
 1.13 “Force Majeure Event” shall have the meaning set forth in
Section 18.13. 
 1.14 “GAAP” means U.S. generally accepted accounting principles.

 1.15 “Governmental Entity” or “Governmental Entities” means any
(i) federal, state, local, foreign or international government; (ii) court, arbitral or other tribunal or governmental or quasi-governmental authority of any nature (including any governmental agency, political subdivision,
instrumentality, branch, department, official or entity); or (iii) body exercising, or entitled to exercise, any administrative, executive, judicial or legislative, police, regulatory, or taxing authority or power of any nature pertaining to
government. 
 1.16 “IND” means an investigational new drug application, as defined in the United States
Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder, where such application is for a Licensed Product. 
 1.17 “Indemnified Party” shall have the meaning set forth in Section 15.2.1. 
 1.18 “Indemnifying Party” shall have the meaning set forth in Section 15.2.1. 
 1.19 “Knowledge” means actual knowledge. 
 1.20
“License” shall have the meaning set forth in Section 2.1. 
 1.21
“Licensed Products” means Captisol-enabled® Amiodarone [***]and all formulations for all
uses [***]. A product that is a Licensed Product in any jurisdiction is a Licensed Product in all jurisdictions. 
 1.22
“Losses” shall have the meaning set forth in Section 15.1. 
 1.23 “Management
Committee” shall have the meaning set forth in Section 3.1. 
 1.24 “NDA” means
a new drug application, as defined in the United States Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder, where such application is for a Licensed Product. 

1.25 “Net Sales” means, for any Royalty Payment Period, the sum of: 

1.25.1 gross revenues invoiced by Prism or its authorized sublicensee during the Royalty Payment Period on the first arm’s length
sale for commercial use of Licensed Products, whether by Prism or its authorized sublicensee, to an unaffiliated third party (“Product Sales”), less only: (1) normal and customary quantity, trade or cash allowances/discounts,
credits or volume discounts given in connection with the sale of Licensed Products; (2) credits actually 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -3-

 
allowed for returns of Licensed Products sold; (3) normal and customary chargebacks, rebates and refunds actually granted and taken; (4) freight and insurance to the extent separately
identified on the invoice, (5) sales and other excise taxes and duties related to or in connection with the sale, transportation or delivery of the Licensed Products (taxes assessed against Licensee’s income are not deductible in
calculating Net Sales), and (6) uncollectible accounts receivable not to exceed [***]% of gross revenues invoiced during the prior [***] month period, provided that if there is less than [***]month history of invoiced sales, then the multiplier
shall be the actual gross revenues invoiced commencing with the first commercial sale. The deductions set forth in the previous subsections 1-6 shall be determined in accordance with GAAP and itemized on the Quarterly Royalty Reports; and

 1.25.2 milestones, fees and other consideration paid to Prism by any sublicensee of Prism’s rights under the License
during the Royalty Payment Period; provided, however, that this Section 1.26.2 shall not include any amount that is calculated based on Product Sales. By way of example and not limitation, Net Sales shall not include any royalty
paid to Prism based on a sublicensee’s Product Sales if Prism also pays a Royalty on the same Product Sales made by such sublicensee. 
 1.26 “Party” means individually CyDex or Prism, as the context dictates, and “Parties” means collectively, CyDex and Prism. 

1.27 “Patent(s)” means any and all patents and patent applications filed in the Territory as
of the Effective Date which are owned by or licensed to CyDex with the right to sublicense, and which claim the product known as Captisol-enabled® Amiodarone (and all polymorphs and active metabolites of amiodarone known by CyDex (or its agents) as of the Effective Date) for claimed uses in [***] and the
developing, marketing, commercializing, manufacturing, making, having made, using, distributing, selling, offering for sale, importing or exporting thereof; together with all patents that in the future issue therefrom in any country of the
Territory, including utility, model and design patents and certificates of invention and all continuations, continuations-in-part, reissues, re-examinations, renewals, extensions, substitutions, confirmations or additions to any such patents and
patent applications, extensions, divisionals, improvements as of the Effective Date, ancestors, descendents and foreign counterparts of any of the foregoing, whether or not pending on the Effective Date, and including, without limitation, any other
application (U.S. or foreign) claiming priority from or through any of the foregoing. For the avoidance of doubt, the Patents include, as of the Effective Date, but are not limited to, the patents and patent applications set forth on
Exhibit A. 
 1.28 “Person” means any individual, corporation, partnership, limited
liability company, joint venture, trust, business association, organization, governmental entity, or other entity, including any successor or assigns (by merger or otherwise) of any such entity. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -4-

 1.29 “Prism” means Prism, and any, subsidiary or any other entity in
which Prism owns, directly or indirectly, more than 50% of the voting securities, partnership, or other ownership interest. 

1.30 “Product Copyrights” means all registered and unregistered copyrights which are owned by, controlled by or
licensed to CyDex with the right to sublicense as of the Effective Date or acquired by CyDex during the Term related to the Licensed Products in the Field in the Territory, including both published works and unpublished works. 

1.31 “Product Intellectual Property” means the Product Technology, Patents, the Product Trademarks, and the
Product Copyrights. 
 1.32 “Product Medical Materials” means any of the following: (i) all adverse
event reports related to the Licensed Products, including any correspondence with the FDA, reports or other documents relating thereto, (ii) all data, information and files relating to the adverse· experiences relating to the Licensed
Products and (iii) all medical responses relating to the Licensed Products, and written, telephone and personal contact inquiries relating to the Licensed Products. 
 1.33 “Product Sales” shall have the meaning set forth in Section 1.26. 
 1.34 “Product Technology” means, in all cases which are owned by, controlled by or licensed to CyDex with the right to sublicense as of the Effective Date or acquired by CyDex
during the Term, all inventions (patentable or unpatentable) regardless of whether patent rights have yet been obtained or applied for, Specifications, technical data, clinical data, know-how, research and development information, knowledge and
other information, whether in existence on the Effective Date or in the future related to, or are desirable for, or are necessary or useful for the development, manufacture, formulation, reformulation, packaging, testing, marketing, use,
distribution, commercialization, offer for sale, sale, import and export of the Licensed Products in the Field in the Territory, but excluding any common industry practice, process or procedure. 

1.35 “Product Trademarks” means all of CyDex’s trademarks (whether registered or unregistered) in the
Territory related to any Licensed Product that are owned by, controlled by or licensed to CyDex with the right to sublicense as of the Effective Date or acquired by CyDex during the Term, including but not limited to those trademarks set forth on
Exhibit B. 
 1.36 “Quarterly Royalty Reports” shall have the meaning set forth in
Section 9.4.2. 
 1.37 “Registrations” shall mean all the pending, withdrawn and/or approved
applications, including but not limited to INDs, NDAs and orphan drug applications and designations, registrations and approvals for each of the Licensed Products currently in the name of CyDex and filed with the FDA or any other Regulatory
Authority, including all information therein, each as more particularly described in Exhibit C. 
 1.38
“Regulatory Authority” shall mean any Governmental Entity in any country of the Territory competent to approve pharmaceutical products for manufacturing, marketing, distribution and sale in any country of the Territory and/or
to approve the price for pharmaceutical products to be sold in any country of the Territory. 

  
 -5-

 1.39 “Royalties” or “Royalty” shall have the
meaning set forth in Section 9.2. 
 1.40 “Royalty Payment Period” shall have the meaning
set forth in Section 9.4.1. 
 1.41 “Specifications” shall mean the specifications,
formulations, recipes and manufacturing instructions for Licensed Products as known at the Effective Date and from time to time during the Term changed, altered, amended or repealed. 

1.42 “Term” shall have the meaning set forth in Section 2.3 below. 

1.43 “Termination Date” shall have the meaning set forth in Section 17.1.2. 

1.44 “Territory” is worldwide. 
 1.45 “U.S.” means the United States of America. 
  

	2.	LICENSE. 

 2.1
License Grant. Subject to the terms and limitations of this Agreement, CyDex grants to Prism a sole and exclusive license, with the right to grant sublicenses, under the Product Intellectual Property, to develop, market, manufacture,
make, have made, use, distribute, commercialize, sell, offer to sell, import and export the Licensed Products (the “License”) in the Field of Use and throughout the Territory. 

2.2 Nature of Exclusivity. This license grant is exclusive even against CyDex, except that CyDex remains free to practice
the Patents in the course of rendering goods or services to Prism or any of Prism’s successors, assigns, licensees or customers in accordance with Prism exercising its rights under this License. 

2.3 Term. Unless terminated in accordance with this Agreement, this License shall commence as of the Effective Date and
shall remain in force and effect in perpetuity (“Term”). 
 2.4 Right to Sublicense. Prism has
the right to sublicense, in whole or in part, its rights under the License; provided that each sublicense shall include terms and provisions which protect CyDex’s rights and interests substantially to the extent provided in
Section 6.1, Article 8, Article 14, and Section 17.2.2(b) of this Agreement. 
  

	3.	MANAGEMENT COMMITTEE. 

3.1 The Parties shall establish a committee of up to six (6) of members which shall be designated and agreed upon in writing by each
of Prism and CyDex and each of whom shall be senior executives of or experienced professional counsel to the appointing Party, provided that such professional counsel is (a) bound to protect the confidentiality of the Confidential Information
of the other Party at least to the extent provided in Article 14 and (b) obligated to assign to the appointing Party any intellectual property developed in the course of its relationship with the appointing Party which shall be
further assigned, if necessary, and owned in accordance with Article 6 (the “Management Committee”). The Parties shall work through the Management Committee to address issues related to obtaining legal and regulatory approvals
for the Licensed 

  
 -6-

 
Products. The initial Management Committee is set forth on Schedule 3.1. At any time, a Party may replace one or more of its designees to the Management Committee by written notice to
the other Party. The Management Committee shall meet quarterly (or more frequently as deemed necessary by the Management Committee), in a location or by telephone as mutually agreed by the Parties, to share information on the status of the
development and commercialization of the Products in the Field in the Territory. The location of the meetings shall take place at Prism’s principal office location. The Management Committee shall also discuss any requests by Prism for
assistance from CyDex pursuant to this Agreement. 
  

	4.	DATA DELIVERY AND TRANSFER OF SPONSORSHIP. 

 4.1 Data Delivery. CyDex shall deliver to Prism no later than [***] days after the Effective Date a copy of all books and records, then in CyDex’s possession, control or use, related to
the Product Medical Materials, the Product Intellectual Property and FDA Communication, including but not limited to, back up files and materials, relating to regulatory filing and compliance, and the research, development, pre-clinical and clinical
studies (including pending, completed and discontinued studies), testing, analysis, marketing, use, off-label use, sale or distribution of the Licensed Products. Such books and records shall be catalogued and identified appropriately by CyDex and
delivered to Prism in a complete and orderly fashion, accompanied by a master list identifying the name and contents of each individual file. 
 4.2 Transfer of Sponsorship. Cydex shall promptly after the Effective Date send written notice as reasonably requested by Prism to the FDA transferring the sponsorship of the Registrations
to Prism and Prism shall promptly after the Effective Date send written notice, as reasonably requested by CyDex or at its own discretion, to the FDA assuming all obligations thereunder, and such notices shall have an effective date that is
approximately [***] days after the Effective Date (or such other date as may be agreed to by the Parties). CyDex shall reasonably assist Prism with the preparation and filing of all amendments to INDs, NDAs and orphan drug designations related to
the Licensed Products. The Parties shall coordinate with one another and shall send such notices simultaneously, and each Party shall deliver a copy of its FDA notice to the other Party. CyDex shall promptly furnish to Prism the Registrations, to
the extent not previously transferred, and the books and records relating thereto. 
  

	5.	PRISM’S RESPONSIBILITIES; CYDEX ASSISTANCE; MANUFACTURING AGREEMENT. 

 5.1 Prism’s Responsibilities. 
 5.1.1 Prism shall be solely
responsible for, exercising commercially reasonable discretion, the developing, marketing, offering for sale, sale, advertising, promotion, distribution, making, having made, manufacturing, exporting, importing, and all other exploitation of the
Licensed Products in the Territory. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -7-

 5.1.2 Prism shall have the sole and absolute discretion to develop the Licensed Products for
purposes of obtaining regulatory approvals and commercializing and selling the Licensed Products in the Field in the Territory, subject to commercially reasonable efforts and compliance with the terms and conditions of this Agreement and applicable
Laws, rules and regulations. Except as otherwise set forth in this Agreement, Prism shall bear all expenses it incurs with respect to its development of the Licensed Products after the Effective Date. 

5.1.3 Prism shall be responsible for obtaining, at its own expense, all applicable legal and regulatory approvals for the Licensed
Products, including but not limited to all FDA and other Regulatory Authority permits and approvals, in all jurisdictions in which Prism seeks to make, use or sell the Licensed Products. 

5.1.4 During the Term, Prism will be responsible for ongoing safety monitoring of the Licensed Products and for regulatory compliance of
the Licensed Products, the NDA and the IND. 
 5.2 CyDex Assistance. If Prism reasonably requests (through the
Management Committee or otherwise) that CyDex provide assistance to Prism’s preparation and filing of any document or other information with the FDA or any other Regulatory Authority of filings required to be filed by Prism for the development,
commercialization, manufacture, marketing, distribution, offer for sale, sale, import or export of the Licensed Products, then CyDex shall provide such assistance to Prism. CyDex will assist Prism throughout the Term with FDA submissions and
information regarding the Licensed Products to the medical community, customers, manufacturers and as otherwise necessary for Prism to develop, commercialize, manufacture, market, distribute, offer for sale, sell, import, export and/or sublicense
the Licensed Products. Such assistance shall include CyDex’s providing Prism with CyDex’s expertise and reasonable access to CyDex’s employees, consultants and agents, subject to their availability which shall be reasonably provided.

 5.3 Manufacturing Agreement. Prism will be responsible for the identification and selection of one or more
manufacturers for the Licensed Products. CyDex will use its commercially reasonable efforts to assist Prism in the transfer to the selected manufacturer(s) of the process and other Product Intellectual Property necessary to manufacture the Licensed
Products. The ultimate selection of any manufacturer and the negotiation of any manufacturing supply agreement with such manufacturer shall be in the sole right and discretion of Prism. 

 

	6.	PATENT MANAGEMENT. 

 6.1
Marking. Prism shall ensure that the Licensed Products, and all packaging and labeling therefor, as well as all promotional, marketing, and advertising material associated with the Licensed Products, as applicable, bear forms of patent
notice and marking meeting the requirements of the applicable jurisdiction(s) and reasonably acceptable to CyDex. Prism shall provide samples of the foregoing to CyDex upon request 

6.2 Prosecution and Maintenance of Patents as of the Effective Date. CyDex shall retain ownership of all Patents, subject
to this License, that CyDex owns on the Effective Date and CyDex shall continue prosecution of all patent applications related to the Licensed 

  
 -8-

 
Products that are pending as of the Effective Date and shall pay all costs associated therewith. CyDex shall promptly inform Prism of any actions regarding the prosecution of all such patent
applications. [***] and [***] by [***] the [***] of [***], [***] have [***] with respect to [***]. 
 6.3 Maintenance of
Patents after the Effective Date. 
 6.3.1 [***] be [***] for and [***] and [***] with the [***] of the [***] the [***].
During the Term, CyDex shall not abandon any of the Patents without first providing prior written notice to Prism of such intention to abandon (which notice shall, in any event, be given no later than [***] days prior to the next deadline for any
action that may be taken with respect to the Patent in the relevant patent office) and such Patent shall be assigned by CyDex to Prism, at Prism’s option. 
 6.3.2 During the Term, Prism shall have the right, in its sole and absolute discretion with respect to any determination, to secure patent protection for any intellectual property, arising out of the
License, invented or created by Prism or on its behalf (and assigned or assignable to it). 
 6.3.3 With respect to any patent
application filed after the Effective Date, Prism shall be responsible for and pay the costs of prosecution and maintenance of all such Patents. Prism may elect, in its sole and absolute discretion, to discontinue or forgo the prosecution or
maintenance of any Patent. Should Prism so elect, Prism shall give written notice in advance of Prism taking any such action (which notice shall, in any event, be given no later than [***] days prior to the next deadline for any action that may be
taken with respect to the Patent in the relevant patent office) to CyDex. CyDex shall then have the right, in its sole and absolute discretion, to maintain or prosecute such Patent. 

6.4 Intellectual Property Ownership. Any inventions relating to the Licensed Products made during the Term shall be owned
by the inventor and joint inventions shall be owned equally by all inventors, in each case determined by rules of inventorship under United States patent law, or as is otherwise determined by the Parties’ written agreement. All such inventions
arising from any activity conducted by the Parties under this Agreement and associated intellectual property shall be assigned to Prism, at its option, by CyDex (or its agents). The parties agree to obtain such assignments of these inventions from
the inventors as are necessary to satisfy their respective obligations under this Section 6.4. 
  

	7.	ENFORCEMENT AND DEFENSE OF PATENTS. 

 7.1 Notification. Each Party agrees to promptly notify the other Party of their knowledge of any actual or suspected third-party infringement or violation of any of the Patents 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -9-

 
or other Product Intellectual Property, as well as of any claim, demand, invitation to license or other third-party challenge to the Patents or other Product Intellectual Property. 

7.2 Enforcement. 
 7.2.1 Prism is solely responsible, in its sole and absolute discretion, and at its sole expense, for the enforcement and defense of any patent or intellectual property rights that it owns, including but
not limited to patent and other intellectual property interests created by it or on its behalf (and assigned or assignable to it) pursuant to this Agreement. 
 7.2.2 With respect to the Product Intellectual Property licensed to Prism hereunder, except as is provided herein to the contrary, Prism shall be solely responsible for the enforcement and defense of such
Product Intellectual Property, at its sole expense, during the Term. Notwithstanding the foregoing: (a) CyDex agrees to be joined as a party plaintiff, at Prism’s request and as is reasonably required to pursue an enforcement action;
(b) counsel selected by Prism shall be reasonably acceptable to CyDex; (c) Prism shall give CyDex prompt notice that an infringement or other action has been commenced concerning any of the Product Intellectual Property, an opportunity to
review and approve in advance any demand, cease and desist letter or invitation to license, and if commercially practical, at least [***] days prior written notice of its intent to commence an enforcement action; (d) Prism shall give CyOcx
prompt written notice of its decision not to enforce or defend any of the Product Intellectual Property; and (e) Prism shall not enter into any settlement agreement or consent judgment, nor shall it make any material admission relating to
validity or enforceability of any of the Product Intellectual Property or with respect to CyDex which would materially adversely effect CyDex without the prior written consent and approval of CyDex, which shall not be unreasonably withheld. In the
event CyDex joins or is named as a party in any enforcement or defense action, CyDex shall have the right but not the obligation to retain separate counsel at its own expense. Any recovery of damages in any enforcement action by Prism involving the
Product Intellectual Property shall be allocated as follows: (i) first, to the payment of attorney’s fees and other costs and expenses of the litigation; (ii) second, the amount that Prism is responsible for making any required
payments to its sublicensees; (iii) third, the remainder to be divided between Prism and CyDex, with CyDex receiving an amount equal to the remainder multiplied by the Royalty rate applicable to Prism’s Net Sales in the most recent Royalty
Payment Period. In the event [***] to [***] or [***] of the [***] or the [***], [***] the [***] the [***] to [***] or [***] at [***] , as the [***] be, and in the [***] to [***] or [***] and [***] to [***]. 

7.3 Procedure. Each Party, regardless of whether it joins in a legal action, agrees to reasonably cooperate with the other
to assist in the prosecution or defense of any actions described in this Article 7. In addition to any other obligation set forth in this Agreement, each Party shall keep the other regularly informed on developments in any such action in
which it 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -10-

 
participates or obtains information, if the other Party is not involved. With respect to the foregoing actions, each Party shall cooperate with each other in such a manner as to preserve in full
(to the extent possible) the confidentiality of any of the other Party’s Confidential Information and the attorney-client and work-product privileges. In connection therewith, each Party agrees that: (i) the provisions of
Article 14 shall apply to the production of Confidential Information, and (ii) all communications between any Party hereto and counsel responsible for participating in the defense of any third-party claim or with respect to any
action regarding the Product Intellectual Property to the extent such action involves or impacts Prism’s right to develop, commercialize, market, manufacture, distribute, sell, offer for sale, import and/or export the Products in the Field in
the Territory, shall, to the extent possible, be made so as to preserve any applicable attorney-client or work-product privilege. 
  

	8.	TRADEMARKS. 

 8.1 Licensee agrees to comply with any requirements established by Licensor concerning the style, design, display and use of the Licensed Trademarks; to use the registered trademark symbol ® with every use of the mark; and to submit in advance of its use advertising copy, labels, stickers or packaging to
Licensor for approval, which shall not be unreasonably withheld. 
 8.2 When requested, Licensee agrees to send samples of
advertising and promotional materials, as well as promotional and advertising materials bearing or sold under the Product Trademarks and any other documents which may permit Licensor to determine whether the services and trademark uses meet the
standards, specifications and directions approved by Licensor. 
 8.3 Licensee agrees that ownership of the Product Trademarks
and the goodwill relating thereto shall remain vested in Licensor both during the period of this Agreement and thereafter, and Licensee further agrees never to challenge, contest or question the validity of Licensor’s ownership of the Product
Trademarks or any registrations thereof by Licensor. 
 8.4 Licensee agrees to inform Licensor of the use of any marks similar
to the Product Trademarks and any potential infringements of Licensor’s mark which come to its attention. 
 8.5 Prism may
use its own trademark(s), service marks, logos and trade dress for the marketing and sale of the Licensed Products, and it shall be solely responsible for the registration, maintenance, enforcement and defense of any such marks. 

 

	9.	FEES AND ROYALTIES. 

 9.1
In consideration of the rights and license granted pursuant to this Agreement, Prism shall pay to CyDex the following fees (“Fees”) upon the attainment of the milestones set forth in the table below: 

  
 -11-

			
	 a. A one-time Fee upon the [***]
	  	[***]
	 b. A one-time Fee upon the [***]
	  	[***]
	 c. A one-time Fee upon the [***]
	  	[***]
	 d. A one-time Fee upon the [***]
	  	[***]
	 e. A one-time Fee upon [***]
	  	[***]

 9.2 In addition to
its payments of Fees pursuant to Section 9.1, Prism shall pay to CyDex royalties on Net Sales (“Royalty” or “Royalties”) commencing with the first commercial sale of a Licensed Product as follows:

  

			
	a. Subject to the reduction set forth in (c) below, Royalty on annual Net Sales of the Licensed Products on the first [***], in total, paid to Prism during any calendar
year:	  	[***]%
	b. Subject to the reduction set forth in (c) below, Royalty on annual Net Sales of the Licensed Products totaling more than [***]paid to Prism during any calendar year:	  	[***]%
	c. Notwithstanding anything to the contrary herein, at the time that there is no longer regulatory exclusivity in the United States, the Royalty on Net sales of the License Products
shall be reduced [***].	  	

 9.3 Calculation of Royalties. All Royalties payable shall be calculated first in the
currency of the jurisdiction in which payment was made, and then converted into U.S. dollars. The exchange rate for such conversion shall be the rate quoted in The Wall Street Journal on the last business day of the applicable Royalty Payment
Period. 
 9.4 Royalty Payment Periods and Reports. 

9.4.1 Prism shall pay Royalties to CyDex on a quarterly basis, measured by each calendar quarter, beginning with the [***] in [***] of
[***] (“Royalty Payment Period(s)”). Prism shall pay Royalties in full within [***]days after the end each Royalty Payment Period. All Royalties and Fees shall be paid in U.S. dollars and directed to such addresses and payees as
CyDex may designate in writing from time to time. 
 9.4.2 Whether or not Royalties are payable at the end of a Royalty Payment
Period, Prism shall provide to CyDex within [***]days after the end of such Royalty Payment Period a written report (“Quarterly Royalty Report(s)”) summarizing the volume of sales of the Licensed Products in each jurisdiction, gross
revenue paid to Prism on sale of the Licensed Products or other sublicense fees as set forth in Section 1.26.2, deductions to determine Net Sales thereof, Net Sales, and Royalties payable. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -12-

 9.5 Late Payments. Unpaid balances shall accrue interest, from the due date
until paid, at a rate equal to the lesser of (i) the prime rate, as reported in The Wall Street Journal, on the date such payment is due, plus an additional [***] percent ([***]%) or (ii) the maximum rate permitted under applicable
law. 
 9.6 Taxes. All amounts due under this Agreement are exclusive of any applicable taxes, including without
limitation, sales, use, value-added, and withholding taxes, and Prism shall pay or withhold all such taxes as required by law. Notwithstanding the foregoing, any and all withholding taxes or similar charges assessable to Prism on Royalties or other
amounts payable hereunder for sales in the Territory outside of the United States will be deducted from such amount due, will be paid by the payer to the proper taxing authority, and Prism shall use commercially reasonable efforts to obtain proof of
payment of said tax, as well as any other documents or confirmations reasonably required by CyDex to recover any such withholding taxes or parts thereof from the proper tax authorities, and sent to CyDex as evidence of such payment. 

9.7 Audit Rights. Licensee shall make and maintain for a period of at least [***] years records of its sales of Licensed
Products, gross revenues paid to Prism on the sale of Licensed Products and deductions in calculating Net Sales. Licensor, at its expense, shall have the right to inspect, copy and audit (itself or through its representative, subject to a
confidentiality agreement reasonably acceptable to Licensee) such books and records at the premises of Licensee during normal business hours, within [***]business days of notice to Prism of its request to conduct such an inspection or audit. CyDex
may not exercise this right more than [***] in any [***] month period during the Term, and only [***] [***] within the [***] month period after this Agreement expires or is terminated. Prism shall provide reasonable cooperation in the conduct of any
inspection or audit. In the event the audit shows an underpayment of more than [***] percent ([***]%) for any applicable Royalty Payment Period, Licensee shall pay Licensor the amounts underpaid. In addition, in the event the audit shows an
underpayment of more than [***] percent ([***]%) for any applicable Royalty Payment Period, Licensee shall pay Licensor, in addition to the amounts underpaid, the reasonable third party costs of such audit. In the event the audit shows an
overpayment of more than [***] percent ([***]%) for any applicable Royalty Payment Period, Licensor shall pay Licensee the amount of such overpayment less the reasonable third party costs of such audit (not to exceed the amount of the overpayment).
Any amount discovered to be due under an audit shall not give rise to a right to terminate this Agreement for failure to make Royalty Payments if such deficiency is paid within [***]days of the audit report; provided, however, that if Licensee is
not in agreement with the audit report, then the Parties shall resolve such dispute in accordance with Section 18.8 and this Agreement may not be terminable by Licensor for reasons of underpayment until the resolution of such dispute in
Licensor’s favor. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -13-

	10.	 PURCHASE AND SUPPLY OF
CAPTISOL®. 

10.1 Purchase of the Captisol®. During the Term, CyDex shall sell to Prism and/or its designee the [***]. 

10.2 Quality Control. CyDex shall perform routine quality control tests with respect to all Captisol® as required by the FDA, as requested in writing by Prism, or otherwise as CyDex deems necessary in accordance with
its applicable policies, and [***]. CyDex shall permit Prism reasonable access to the copies of the records of such quality control tests performed on each lot or batch of Captisol®. 
 10.3 Captisol® Supply Agreement. The parties agree to negotiate in good faith a Supply Agreement for Captisol® (“Captisol® Supply Agreement”) which shall include terms addressing pricing, safety stock, supply failure procedures, rights and obligations and other normal and
customary terms. The parties agree to enter into a definitive Captisol® Supply Agreement no later than [***].

  

	11.	NOTICE OF SAFETY OR EFFICACY CONDITIONS: 

 11.1 Each Party shall promptly notify the other Party of its Knowledge of any fact, circumstance, condition or knowledge that bears on (i) the safety or efficacy of Captisol® or the Licensed Products or (ii) the safety of any of the Licensed Products. Each Party may use and disclose
such information to the extent necessary to comply with law. 
  

	12.	WARRANTIES; DISCLAIMERS. 

12.1 Representation and Warranties of Both Parties. Each Party represents, and warrants to the other Party that: 

 

	 	(a)	it is a corporation duly organized and validly existing under the laws of the state or country of its incorporation; 

 

	 	(b)	the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all necessary corporate action of
such Party; 

  

	 	(c)	the execution and delivery of this Agreement and the performance by such Party of any of its obligations under this Agreement do not and will not:

  

	 	(i)	 conflict with, or constitute a breach or violation of, any other contractual obligation to which it is a party, any judgment of any court or
governmental body applicable to such Party or its properties, or, to such Party’s Knowledge, any statute, decree, 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -14-

	 	 
order, rule or regulation of any court or governmental agency or body applicable to such Party or its properties, and 

 

	 	(ii)	require any consent or approval of any governmental authority or other person; 

 

	 	(d)	it will, to the best of its knowledge without undertaking a special investigation, disclose to the other Party any material adverse proceedings, claims or actions that
arise that would materially interfere with that Party’s performance of its obligations under this Agreement. 

12.1.1 Representations and Warranties of CyDex. CyDex, as an inducement to Prism to enter into this Agreement, represents,
warrants or covenants to Prism, as applicable, as follows: 
  

	 	(a)	Right to License. CyDex owns or controls the Product Intellectual property and has full right, power and authority, free of any Encumbrance, to grant the
License. As of the Effective Date, CyDex is not aware of any fact or circumstances that the Licensed Products are, in or with respect to the Territory, subject to any restrictions, covenants, licenses other than this Agreement, or judicial and
administrative orders of any kind, which detract in any material respect from the value of the Licensed Products or the Product Intellectual Property, or which could interfere with the use thereof by Prism in the Territory as contemplated by this
Agreement. 

  

	 	(b)	No Inability to Receive Approval. As of the Effective Date, CyDex is aware of no facts that would lead it to conclude that any of the Licensed Products
will be unable to receive Approval or approval from any other Regulatory Authority; provided that clinical development and other regulatory requirements are completed in accordance with all applicable Laws, rules and regulations.

  

	 	(c)	Clear Rights. As of the Effective Date, CyDex has not received any notice and has no Knowledge that (i) the rights to the Product Intellectual
Property or the Licensed Products have been challenged or that there exists any reasonable basis for such a challenge in any judicial or administrative proceeding, or (ii) any person, entity or product has infringed or that any person or entity
intends to infringe any patent rights encompassed by the Licensed Products or the Product Intellectual Property and applicable to the Licensed Products, or (iii) any patent rights or other intellectual property rights, including but not limited
to rights of trademark, trade dress and copyright, have been infringed by CyDex in connection with the Licensed Products or will be infringed by Prism by virtue of exercising the License granted by this Agreement. 

 

	 	(d)	Intellectual Property Rights. 

  
 -15-

	 	(i)	As of the Effective Date, Exhibit A contains a true and correct list of the Patents. The omission of any Patent from this definition shall not prejudice
Prism’s right to such intellectual property pursuant to the License. 

  

	 	(ii)	Exhibit B contains a true and correct list of the Product Trademarks. The omission of any trademark from Exhibit B shall not prejudice
Prism’s right to such trademark pursuant to the License. All of the Product Trademarks listed on Exhibit B as registered or filed have been duly registered in the Territory in the name of CyDex with the appropriate Governmental
Entities and are in full force and effect. 

  

	 	(e)	CyDex has taken commercially reasonable precautions to protect the secrecy and confidentiality of the Product Intellectual Property, other than the Patents, Product
Copyrights and Product Trademarks to the extent publicly known. 

 12.1.2 Litigation. As of the
Effective Date, there is no suit, claim, action, investigation or proceeding pending or, to the Knowledge of CyDex, threatened against CyDex that relates to the Licensed Products or Product Intellectual Property, or challenges or seeks to prevent or
enjoin the License. CyDex has no Knowledge of any settlements, court decisions or agreements involving any third party and existing on the Effective Date that would have a material adverse effect on the Licensed Products. 

12.2 No Brokers. CyDex has not entered into any agreement, arrangement or understanding with any Person or firm which will
result in the obligation of Prism to pay any finder’s fee, brokerage commission or similar payment in connection with the transactions contemplated hereby. 
 12.3 Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE 12, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANT ANY WARRANTIES, EXPRESS OR IMPLIED, AND EACH PARTY
SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	13.	LIMITATION OF LIABILITY. 

NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, AND EXCEPT FOR THE PARTIES’ OBLIGATIONS TO INDEMNIFY AS SET OUT HEREIN
AND EXCEPT FOR INFRINGEMENT OR VIOLATION OF THE OTHER PARTY’S PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OR A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY WITH RESPECT TO
ANY SUBJECT MATTER OF THIS AGREEMENT, UNDER ANY EQUITY, COMMON LAW, TORT, CONTRACT, ESTOPPEL, NEGLIGENCE, STRICT LIABILITY OR OTHER 

  
 -16-

 
THEORY, FOR ANY INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY, INDIRECT OR CONSEQUENTIAL DAMAGES (INCLUDING BUT NOT LIMITED TO DAMAGES RESULTING FROM LOSS OF SALE, BUSINESS, PROFITS, OPPORTUNITY OR
GOODWILL), EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF ANY OF THE FOREGOING DAMAGES. 
  

	14.	CONFIDENTIALITY. 

 14.1
The Parties anticipate that, in the course of their relationship in connection with this Agreement, they are likely to exchange Confidential Information. Each Party agrees to use the other’s Confidential Information only to exercise its rights
and perform its duties pursuant to this Agreement. 
 14.2 Each Party agrees not to disclose the other’s Confidential
Information to third parties without the other’s express prior, written consent, except that each may disclose the other’s Confidential Information: 
 14.2.1 to those of its employees, representatives and agents that it reasonably requires to have access to same in order to perform its obligations and/or exercise its rights under this Agreement,
provided such employees, representatives or agents are bound by obligations of confidentiality comparable to those set forth in this Section 14; and 
 14.2.2 to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications or complying with orders of any court, other Governmental Entity or arbitral body or with
applicable laws or governmental regulations, provided that if a Party intends to make any such disclosure, it shall use reasonable efforts to give reasonable advance written notice to the other Party of such intended disclosure to permit such other
Party to seek such protective orders or other similar relief as may be available in the circumstances. 
 14.3 Each Party agrees
to safeguard the other’s Confidential Information against unauthorized use and disclosure with means at least as stringent as it employs to safeguard its own Confidential Information, and in no event with less than reasonable means. 

14.4 The obligations of confidentiality in this Section 14 are in addition to and not in lieu of any confidentiality
obligations the Parties may owe each other as a matter of underlying law, and the obligations herein shall survive the termination or expiration of this Agreement for so long as the information at issue continues to meet the definition of
Confidential Information set forth in Section 1.6. 
  

	15.	INDEMNIFICATION AND INSURANCE. 

 15.1 Indemnification. 
  

	 	(a)	Indemnification by Licensor. Licensor shall indemnify and hold Licensee and its affiliates, officers, directors, employees, and agents harmless from and
against any and all liability, damage, loss, cost (including reasonable attorneys’ fees) and expenses related to any third-party claims (“Losses”) to the extent arising from or in connection with: 

  
 -17-

	 	(i)	Licensor’s breach of any representation, warranty, covenant or agreement contained in this Agreement; or (ii) any infringement or alleged infringement of
intellectual property rights resulting from Licensee’s authorized use of the Product Intellectual Property; provided, however, that excluded from this Section 15.1(a) is any claim that is a result of willful misconduct or grossly
negligent act of Licensee or breach by Licensee of this Agreement to the extent covered in Section 15.l(b)(i) below. 

  

	 	(b)	Indemnification by Licensee. Licensee, to the extent not caused by, related to or in any way connected with the acts of Licensor, shall indemnify and hold
Licensor and its affiliates, officers, directors, employees, and agents harmless from and against any and all liability, damage, loss, cost (including reasonable attorneys’ fees) and expenses to the extent arising from or in connection with any
third-party claims: (i) Licensee’s breach of any representation, warranty, covenant or agreement contained in this Agreement, or (ii) the development, manufacturing, use, handling advertising, promotion, marketing or sale of Licensed
Products by Licensee or any sublicensee of its rights under this Agreement; provided, however, that excluded from this Section 15.1(b) is any claim that is a result of willful misconduct or grossly negligent act of Licensor or breach by
Licensor of this Agreement to the extent covered in Section 15.l(a)(i) above and excluded from Licensee’s indemnification obligations under Section 15.l(b)(ii) are all matters to the extent covered by Licensor’s
indemnities under Section 15.1(a). 

 15.2 Procedure. 

15.2.1 In order for an indemnified party under this Article 15 (an “Indemnified Party”) to be entitled to
any indemnification provided for under this Agreement, such Indemnified Party will, promptly following the discovery of the matters giving rise to any Loss, notify the indemnifying party under this Article 15 (the “Indemnifying
Party”) in writing of its claim for indemnification of such Loss, specifying in reasonable detail the nature of such Loss and the amount of the liability estimated to accrue therefrom; provided, however, that failure to give such prompt
notification will not affect the indemnification provided hereunder except to the extent the Indemnifying Party will have been actually prejudiced as a result of such failure. Thereafter, the Indemnified Party shall promptly deliver to the
Indemnifying Party, at the Indemnifying Party’s expense, all information and documentation reasonably requested by the Indemnifying Party with respect to such Loss and the Indemnified Party shall cooperate fully with the Indemnifying Party, at
the Indemnifying Party’s expense, in the defense of such claim. 
 15.2.2 If an Indemnified Party gives notice to the
Indemnifying Party pursuant to Section 15.2.1, the Indemnifying Party shall control the defense and settlement of such third-party claim (unless the Indemnifying Party is also a person against whom the third-party claim is made and the
Indemnified Party determines in good faith that joint representation would be inappropriate, in which case the Indemnified Party shall have the right to select separate counsel to participate in the defense of such action on its behalf, and the
Indemnified Party shall bear the 

  
 -18-

 
cost and expense of such separate defense, unless and to the extent the Parties otherwise agree or it is determined through arbitration hereunder that such costs and expense are or were required
to be indemnified by the Indemnifying Party), with counsel selected by the Indemnifying Party that the Indemnified Party consents to as reasonably satisfactory, which consent shall not be unreasonably withheld. The Indemnifying Party shall not, so
long as it diligently conducts the defense of such third party claim be liable to the Indemnified Party under this Article 15 for any fees of other counselor any other expenses with respect to the defense of such third party claim. No
compromise or settlement of such third-party claim may be effected by either Party in a way that prejudices or adversely impacts the other Party without the other Party’s prior written consent, which consent shall not be unreasonably withheld.
Notwithstanding the assumption by the Indemnifying Party of the defense of any third-party claim as provided in this Article 15, the Indemnified Party will be permitted to join such defense and to employ counsel at its own expense. If
notice is given to an Indemnifying Party of the assertion of any third-party claim and the Indemnifying Party does not, within [***] days after the Indemnified Party’s notice is given, give notice to the Indemnified Party of its assumption of
the defense of such third-party claim, the Indemnifying Party will be bound by any determination made in such third-party claim or any reasonable compromise or settlement effected in good faith by the Indemnified Party. Indemnified Party shall have
the right to maintain the defense of such claim or action and the Indemnifying Party shall provide reasonable assistance to the Indemnified Party in the defense of such third party claim and to bear the reasonable cost and expense of such defense
(including attorney’s and experts’ fees and expenses). 
 15.2.3 Notwithstanding the provisions of
Section 18.8, the Parties each consent to the nonexclusive jurisdiction of any court in which a proceeding in respect of a third-party claim is brought by a third party either against Prism or CyDex for purposes of defense of such third
party claim and each Party agrees that process may be served on it with respect to indemnification with respect to such third party claim in accordance with Section 18.12. 

15.2.4 This Article 15 sets forth the Parties’ complete and sole obligations to indemnify one another for Losses arising
from or connected with third party claims. 
 15.3 Insurance. Licensee shall procure and maintain during the term
of this Agreement, commercial general liability insurance, in commercially reasonable amounts, and with the insurance carriers licensed to do business in the jurisdiction where Licensee is located; provided, however, that Licensee shall not be
required to maintain product liability coverage so long as Licensed Products are not being sold or used with humans. 
  

	16.	PUBLICATION. 

 16.1 The
Parties will consult with each other before issuing any press release or otherwise making any public statement or other disclosure with respect to this Agreement. Neither Party will issue any such press release or make any such public statement or
other 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -19-

 
disclosure prior to receiving written approval from the other Party, unless compelled to do so under a regulatory or legal obligation. 

16.2 From time to time, Prism may desire to publish or otherwise publicly announce the results of testing or from the research or
development program involving any Licensed Products orally or in writing. CyDex shall not unreasonably withhold its consent to such publication or announcement. 
  

	17.	TERMINATION. 

 17.1
Termination. 
 17.1.1 Termination by Prism. Prism may terminate this Agreement at any time, without
cause, by giving [***]days prior written notice thereof to CyDex. 
 17.1.2 Termination by CyDex. CyDex may
terminate this Agreement if an NDA for any of the Licensed Products has not been submitted to the FDA on or before the [***] year anniversary of the Effective Date (the “Termination Date”); provided, however, that CyDex must give
Prism written notice of such termination within [***]days after the Termination Date. 
 17.1.3 Termination by Either
Party. 
  

	 	(a)	Either Party may terminate this Agreement upon a material or continuing breach of this Agreement by the other Party by giving [***]days prior written notice of
termination, stating the claimed breach with specificity, and termination shall be effective as of the end of such [***]-day notice period unless the breach is then substantially cured or the breaching Party has commenced such actions necessary to
cure the breach. 

  

	 	(b)	Either Party may terminate this Agreement immediately by giving written notice of termination in the event of a Default. Events of Default shall occur if the other
Party: (a) makes or attempts to make an assignment for the benefit of creditors; (b) becomes the subject of voluntary or involuntary bankruptcy proceedings, and such proceedings are not dismissed within [***]days, or if this License or the
rights hereunder are conveyed out of bankruptcy; or (c) is convicted of any criminal offense in connection with the business associated with the Licensed Products. 

17.2 Effects of Termination or Expiration. 
 17.2.1 Upon termination or expiration, each Party shall return to the other all of the other’s Confidential Information that is capable of being returned, and destroy, in a manner that prevents
undeletion, Confidential Information that is not capable of being transported. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -20-

 
Except as otherwise provided herein, neither Party may use the other’s Confidential Information after termination or expiration of this Agreement. Notwithstanding anything to the contrary,
Prism may retain and use original Confidential Information to the extent that it relates to or is connected with any intellectual property owned by Prism. 
 17.2.2 If requested by CyDex within [***]days of the termination of this Agreement pursuant to Section 17.1.1, Section 17.l.2, or by CyDex pursuant to Section 17.1.3,
Prism shall: 
  

	 	(a)	[***] to the [***] or [***] the [***] of the [***], the [***] and the [***] ) to [***] and [***], as reasonably requested [***] , to the FDA or any other applicable
Regulatory Authority assuming all obligations thereunder and such notices shall have an effective date that is [***]days after the date of termination of this Agreement (or such other date as may be agreed to by the Parties). The Parties shall
coordinate with one another and shall send such notices simultaneously, and each Party shall deliver a copy of its such notice of the FDA or any other applicable Regulatory Authority to the other Party. 

 

	 	(b)	[***] to CyDex [***] and [***] including [***] and [***], relating to [***] and [***], and the [***] and [***] studies (including [***] and [***] ), [***] or [***] of
the [***]. 

  

	 	(c)	[***] to CyDex a [***] under [***] filed by Prism pursuant to Section [***] above, to make, have made, use, sell, offer to sell or import the Licensed
Products. 

  

	 	(d)	at the option of CyDex, [***] to CyDex [***] as of the date of termination to any or all of the patents abandoned by CyDex and [***] to [***] pursuant to
Section [***] above. 

 17.2.3 Upon termination of this Agreement, Prism shall have no further
payment, management, development obligations with respect to the Licensed Products. 
  

	18.	MISCELLANEOUS. 

 18.1
Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties on the subject matter herein, and it supersedes all prior agreements 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -21-

 
and understandings between the Parties with respect to its subject matter. No amendment or modification to this Agreement shall be effective unless in writing signed by an authorized
representative of each Party. 
 18.2 Assignment. Neither Party may assign its rights or delegate its obligations
under this Agreement without the express prior written consent of the other Party, except that either Party’s rights and obligations may succeed by operation of law to the surviving entity in a merger or consolidation in which it participates
or to a successor of all or substantially all of either Party’s assets or stock. Any unauthorized assignment or transfer of this Agreement shall be void. Subject to the foregoing, the rights and liabilities of the Parties will bind and inure to
the benefit of their respective successors, permitted assigns, insurers and reinsurers. 
 18.3 Relationship. The
Parties are independent entities. Nothing contained in this Agreement or the Parties’ conduct hereunder shall be construed to create a relationship of partners, joint venturers, principal and agent or employer/employee. Neither Party shall have
any right, power or authority, express or implied, to bind the other Party. 
 18.4 Survival. 

18.4.1 The representations and warranties contained in Article 12 shall survive the execution and delivery of this Agreement
and remain true during the Term, except with respect to those representations and warranties which are limited to the Effective Date or which otherwise are limited to a particular time or which refer to past actions, which shall be true as of the
Effective Date. 
 18.4.2 Each Party’s covenants and agreements under this Agreement shall remain in effect only during the
Term until performed by such Party, subject to any conditions to performance, discharge of the duty to perform and similar traditional contract interpretation principles. 
 18.4.3 Provisions of this Agreement that, by their nature, survive its termination or expiration shall so survive, including without limitation Sections 1 (Definitions), 17.2 (Effects of Termination or
Expiration), 13 (Limitations), 14 (Confidentiality), 15.1-15.2 (Indemnity), and 18 (Miscellaneous Terms). 
 18.5
Severability. If any provision of this Agreement or portion thereof is finally held by a court of competent jurisdiction to be unenforceable, void, invalid, or otherwise contrary to law or equity, the Parties agree that such provision
or portion thereof shall be reformed automatically as necessary to cure such defect, or if necessary to delete such provision or portion thereof, and that the remainder of this Agreement shall continue in full force and effect 

18.6 Waiver. The observance of any provision of this Agreement may be waived (either generally or any particular instance
and either retroactively or prospectively) only in a writing signed by both Parties. The failure of either Party to enforce its rights under this Agreement at any time for any period shall not be construed as a waiver of such rights. 

18.7 Fees and Expenses. Each Party will bear all fees, costs and expenses incurred by it in respect of the negotiation,
drafting and execution of this Agreement and the consummation 

  
 -22-

 
of the transactions contemplated thereby, including without limitation the fees and disbursements of its legal, financial and other advisors and any and all filing fees incurred by each of them
in connection with obtaining all required approvals from and submitting all required filing to, all governmental and other regulatory agencies. 
 18.8 Arbitration. Any controversy, dispute or claim arising out of, in connection with, or in relation to the interpretation, performance or breach of this Agreement, or any amount due
hereunder, including, without limitation, any claim based on contract, tort or statute shall be settled as follows: The Management Committee shall initially meet to attempt to resolve disputes. If the Management Committee cannot resolve such
disputes within [***]days after either Party requests such a meeting, then either Party may request that the chief executive officer of each Party meet to attempt to resolve such dispute. If the chief executive officers cannot resolve such disputes
within [***]days after either Party requests such a meeting, then such controversy, dispute or claim shall be settled, solely and exclusively, by arbitration. Any arbitration pursuant to this Agreement shall be conducted in [***] before and in
accordance with the then existing Commercial Dispute Resolution Procedures through the American Arbitration Association, using an arbitrator mutually selected by CyDex and Prism from a list of those designated by the American Arbitration Association
or, if the Parties disagree, otherwise appointed by the American Arbitration Association. At any time, a Party may seek or obtain preliminary, interim or conservatory measures from the arbitrators or from a court. Any arbitration shall be final and
binding. The findings shall be delivered in a written opinion with findings of facts based on the record. Any judgment upon any interim or final award or order rendered by the arbitrator may be entered by any State or Federal court having
jurisdiction thereof. The Parties intend that any agreement pursuant hereto to arbitrate be valid, enforceable and irrevocable. Each Party in any arbitration proceeding commenced hereunder shall bear such Party’s own costs and expenses
(including expert witness and attorneys’ fees) of investigating, preparing and pursuing such arbitration claim. Notwithstanding the foregoing, neither Party shall be bound to follow the dispute resolution process described in this
Section 18.8 with respect to any dispute for which interim equitable relief from a court is necessary to prevent serious and irreparable injury to a Party. 
 18.9 Governing Law. This Agreement shall be governed and construed in accordance with the laws of the state of Delaware, and without regard to its choice of law rules. 

18.10 Headings. The headings used in this Agreement are for convenience only and are not to be used in interpreting the
rights and obligations of the Parties under this Agreement. 
 18.11 Counterparts; Facsimile. This Agreement shall
be effective upon full execution by facsimile or original, and a facsimile signature shall be deemed to be and shall be as effective as an original signature. This Agreement may be executed in any number of counterparts, each of which will be deemed
an original, but all of which taken together shall constitute one single agreement between the Parties. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -23-

 18.12 Notices. Any notice or other communication required or permitted to be
given hereunder, shall be in writing and shall be deemed to be given when delivered by hand or commercial overnight courier service with tracking capabilities or sent by certified mail (return receipt requested), all of the foregoing costs and
postage prepaid, to the Parties at the addresses set forth below, or such other address as a Party may specify for the other by written notice; 
  

			
	 For CyDex:
 Attention: John M.
Siebert Ph.D.
 President and CEO

CyDex, Inc.
 10513 W. 84th Terr.
 Lenexa, Kansas 66214
	 	 For Prism:
 Attention:
Warren D. Cooper
 President and CEO

Prism Pharmaceuticals, Inc
 1150 First Ave.,
Suite 1050,
 King of Prussia, PA, 19406

		
		 	 copy to:
 Dinsmore &
Shohl LLP
 Attn: Paul R. Mattingly, Esq.

1900 Chemed Center
 225 East Fifth
Street
 Cincinnati, Ohio 45202

 18.13 Force Majeure. Neither Party hereto shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, which may include but not be limited to fire, floods, embargos, war, acts of war
(whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God, omissions or delays in acting by any Governmental Entity (including the FDA and Regulatory Authorities) or the
other Party hereto (collectively, “Force Majeure Event”). 
 18.14 Drafting. Each Party and its
counsel has reviewed and had the opportunity to contribute to the drafting of this Agreement, and the rule of construction providing that any ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation of
this Agreement. This Agreement shall be construed as drafted by both Parties. 
 IN WITNESS WHEREOF, the Parties hereto have
caused this Agreement to be signed by their duly authorized representatives. 
  

									
	CYDEX, INC.	 		 	PRISM PHARMACEUTICALS, INC.
					
	By:	 	 /s/ John M. Siebert
	 		 	By:	 	 /s/ Warren D. Cooper

		 	John M. Siebert, Ph.D., President and CEO	 		 		 	Warren D. Cooper, President and CEO
			
	Dated: 4 January, 2006	 		 	Dated: 1/4/2006

  
 -24-

 SCHEDULE 3.1 
 Initial Management Committee 
 Prism’s designees to the Management Committee:

 Kathleen DeLawrence 
 Dan
Cushing 
 Robert Falconer 

CyDex’s designees to the Management Committee: 
 Jose Rodriguez 
 Jerry Mosher 

  
 -25-

 EXHIBIT A 

LICENSED PATENTS 
 EXHIBIT A 
 LICENSED PATENTS 

 

					
	 Country
	  	Patent Number	 	Application Number
	[***]	  		 	[***]
	[***]	  		 	[***]
	[***]	  		 	[***]
	[***]	  		 	[***]
	[***]	  		 	[***]
	[***]	  		 	[***]
	[***]	  		 	[***]
	[***]	  	[***]	 	[***]
	[***]	  	[***]	 	[***]
	[***]	  		 	

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -26-

 EXHIBIT B 

TRADEMARKS 
 [***]

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -27-

 EXHIBIT C 

REGISTRATIONS 
 [***] 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 -28-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]